Research
Hormonal
Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces greater weight loss than Semaglutide in patients with type 2 diabetes.
If you have type 2 diabetes and obesity, ask your doctor about Tirzepatide. It is a once-weekly injection that combines two hormones to help you lose more weight than Semaglutide. It starts at a low dose and increases every few weeks to reach the maximum dose.
GoodSupportsHIGH confidence
An open-label, 40-week, phase III randomized trial comparing weekly tirzepatide and semaglutide in type 2 diabetes mellitus patients indicated that reductions in body weight were greater and statistically significant with tirzepatide than with semaglutide in the secondary endpoints.
Why this rating
Based on a cited phase III randomized trial.
Source
Obesity and Current Treatment Approaches: A Comprehensive Review
Karthik Mathialagan et al. · Journal of Translational Gastroenterology · 2024
DOI 10.14218/jtg.2023.00040
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Weekly subcutaneous semaglutide (2.4 mg) produces significantly greater mean weight loss (15.4%) compared to daily subcutaneous liraglutide (3.0 mg, 6.4%) in patients with overweight or obesity.Good
- Bariatric surgery (Laparoscopic Sleeve Gastrectomy and Roux-en-Y Gastric Bypass) provides effective and sustainable weight loss, with Roux-en-Y showing greater long-term excess weight loss but higher morbidity.Good
- Combination pharmacotherapy for obesity is significantly more effective than monotherapy.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →